Can a Bone-Building drug save your new knee?
NCT ID NCT04167163
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether the drug abaloparatide (Tymlos) can reduce bone loss after total knee replacement in people with osteoporosis or osteopenia. 58 participants took the drug for 18 months. The main goal was to see if bone density around the new knee improved compared to before surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- abaloparatide (Tymlos)
- What this could lead to
- If it works, this could point toward a way to prevent bone loss around a new knee joint, improving implant longevity and reducing fracture risk.
- What could go wrong
- This is a small, early-phase study (58 people) with no placebo group, so results may not be conclusive. The drug is already approved for osteoporosis but not for this specific use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTHROPLASTIES, KNEE REPLACEMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Wisconsin
Madison, Wisconsin, 53705, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can discarded bone reveal the secrets to stronger bones?
- Could a common diabetes drug weaken your bones?
- A tastier calcium chew might boost bone Health—But does it work?
- Exercise program aims to steady the stance of osteoporosis patients
- Can a Bone-Strengthening infusion given right after hip surgery prevent a second break?
- Can a single dose of zoledronic acid safely treat bone loss in dialysis patients?